ReviewNature reviews. Molecular cell biology2018
Chromatin dependencies in cancer and inflammation.
Review in Nature reviews. Molecular cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Targeting MORC2 activates transposable element-mediated viral mimicry and potentiates immune checkpoint blockade in triple-negative breast cancer.Molecular cancer · 2026Article
- PR inhibition stimulates G6PD expression to enhance malignancy in luminal breast cancer.Cell death & disease · 2025Article
- Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug Delivery Systems for Synergistic Efficacy and Precision Modulation.International journal of nanomedicine · 2025Review
- Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.Frontiers in pharmacology · 2025Review
- AURKB promotes immunogenicity and immune infiltration in clear cell renal cell carcinoma.Discover oncology · 2024Article
- A PRMT5-ZNF326 axis mediates innate immune activation upon replication stress.Science advances · 2024Article
- Development and validation of a chromatin regulator signature for predicting prognosis hepatocellular carcinoma patient.Journal of gastrointestinal oncology · 2024Article
- Construction and validation of a chromatin regulator-related gene signature for prognostic and therapeutic significance of clear cell renal cell carcinoma.Translational cancer research · 2024Article
- Combination Therapy with a TLR7 Agonist and a BRD4 Inhibitor Suppresses Tumor Growth via Enhanced Immunomodulation.International journal of molecular sciences · 2024Article
- Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy.Theranostics · 2024Article
- Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment.Genes · 2023Review
- Pan-cancer landscape of epigenetic factor expression predicts tumor outcome.Communications biology · 2023Article
- Dependency of NELF-E-SLUG-KAT2B epigenetic axis in breast cancer carcinogenesis.Nature communications · 2023Article
- Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.Cancers · 2023Review
- Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma.Frontiers in immunology · 2023Article
- Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma.Pathology oncology research : POR · 2023Article
- The Systemic Inflammation Score is Associated with the Survival of Patients with Prostate Cancer.Journal of inflammation research · 2023Article
- Article
- Myeloid cell-specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation.EMBO reports · 2022Article
- Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.Hereditas · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple cell-signalling pathways converge on chromatin to induce gene expression programmes. The inducible transcriptional programmes that are established as a result of inflammatory or oncogenic signals are controlled by shared chromatin regulators. Therapeutic targeting of such chromatin dependencies has proved effective for controlling tumorigenesis and for preventing immunopathologies that are driven by overt inflammation. In this Review, we discuss how chromatin dependencies are established to regulate the expression of key oncogenes and inflammation-promoting genes and how a better mechanistic understanding of such chromatin dependencies can be leveraged to improve the magnitude, timing, duration and selectivity of cell responses with the aim of minimizing unwanted cellular and systemic effects. Recently, exciting progress has been made in cancer immunotherapy and in the development of drugs that target chromatin regulators. We discuss recent advances in clinical trials and the challenge of combining immune-cell-based therapies and epigenetic therapies to improve human health.
Indexed as
Identifiers
29184195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.